Secretin-receptor and secretin-receptor-variant expression in gastrinomas: Correlation with clinical and tumoral features and secretin and calcium provocative test results

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 11, 2007, Pages 4394-4402

  Long, Scott H ^a   Berna, Marc J ^a,c   Thill, Michelle ^b   Pace, Andrea ^c   Pradhan, Tapas K ^a   Hoffmann, K Martin ^d   Serrano, Jose ^a   Jensen, Robert T ^a,e  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL EYE INSTITUTE   (United States)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CALCIUM; GASTRIN; HORMONE RECEPTOR; MESSENGER RNA; SECRETIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DEMOGRAPHY; DISEASE DURATION; FEMALE; GASTRINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE ENDOCRINE NEOPLASIA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROVOCATION TEST; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DENSITY; STATISTICAL ANALYSIS; STOMACH ULCER; WESTERN BLOTTING; ZOLLINGER ELLISON SYNDROME;

EID: 35948949052     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-0986     Document Type: Article

References (47)

1. Jensen RT, Doppman JL, Gardner JD 1986 Gastrinoma. In: Go VLW, Brooks FA, DiMagno EP, Gardner JD, Lebenthal E, Scheele GA, eds. The exocrine pancreas: biology, pathobiology and disease. 1st ed. New York: Raven Press; 727-744
2. McGuigan JE, Wolfe MM 1980 Secretin injection test in the diagnosis of gastrinoma. Gastroenterology 79:1324-1331
3. Deveney CW, Deveney KS, Jaffe BM, Jones RS, Way LW 1977 Use of calcium and secretin in the diagnosis of gastrinoma (Zollinger-Ellison syndrome). Ann Intern Med 87:680-686
4. Berna MJ, Hoffmann KM, Long SH, Serrano J, Gibril F, Jensen RT 2006 Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Evaluation of diagnostic criteria, proposal of new criteria and correlations with clinical and tumoral features. Medicine (Baltimore) 85:331-364
5. Brady III CE 1991 Secretin provocation test in the diagnosis of Zollinger-Ellison syndrome. Am J Gastroenterol 86:129-134
6. Lamers CB, Van Tongeren JHM 1977 Comparative study of the value of calcium, secretin, and meal stimulated increase in serum gastrin in the diagnosis of the Zollinger-Ellison syndrome. Gut 18:128-134
7. Ding WQ, Kuntz S, Bohmig M, Wiedenmann B, Miller LJ 2002 Dominant negative action of an abnormal secretin receptor arising from mRNA missplicing in a gastrinoma. Gastroenterology 122:500-511
8. Gibril F, Schumann M, Pace A, Jensen RT 2004 Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. A prospective study of 107 cases and comparison with 1009 patients from the literature. Medicine 83:43-83
9. Roy P, Venzon DJ, Shojamanesh H, Abou-Saif A, Peghini P, Doppman JL, Gibril F, Jensen RT 2000 Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine 79:379-411
10. Benya RV, Metz DC, Venzon DJ, Fishbeyn VA, Strader DB, Orbuch M, Jensen RT 1994 Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type 1. Am J Med 97:436-444
11. Roy P, Venzon DJ, Feigenbaum KM, Koviack PD, Bashir S, Ojeaburu JV, Gibril F, Jensen RT 2001 Gastric secretion in Zollinger-Ellison syndrome: correlation with clinical expression, tumor extent and role in diagnosis-a prospective NIH study of 235 patients and review of the literature in 984 cases. Medicine (Baltimore) 80:189-222
12. Termanini B, Gibril F, Reynolds JC, Doppman JL, Chen CC, Stewart CA, Sutliff V, Jensen RT 1997 Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 112:335-347
13. Thom AK, Norton JA, Doppman JL, Chang R, Miller DL, Jensen RT 1992 Prospective study of the use of intraarterial secretin injection and portal venous sampling to localize duodenal gastrinomas. Surgery 112:1002-1008
14. Sugg SL, Norton JA, Fraker DL, Metz DC, Pisegna JR, Fishbeyn V, Benya RV, Shawker TH, Doppman JL, Jensen RT 1993 A prospective study of intraoperative methods to diagnose and resect duodenal gastrinomas. Ann Surg 218:138-144
15. Fishbeyn VA, Norton JA, Benya RV, Pisegna JR, Venzon DJ, Metz DC, Jensen RT 1993 Assessment and prediction of long-term cure in patients with Zollinger-Ellison syndrome: the best approach. Ann Intern Med 119:199-206
16. Yu F, Venzon DJ, Serrano J, Goebel SU, Doppman JL, Gibril F, Jensen RT 1999 Prospective study of the clinical course, prognostic factors and survival in patients with longstanding Zollinger-Ellison syndrome. J Clin Oncol 17:615-630
17. Norton JA, Alexander HR, Fraker DL, Venzon DJ, Jensen RT 2004 Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases or survival in patients with Zollinger-Ellison syndrome (ZES)? Ann Surg 239:617-626
18. Sutliff VE, Doppman JL, Gibril F, Yu F, Serrano J, Venzon DJ, Jensen RT 1997 Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns. J Clin Oncol 15:2420-2431
19. Furukawa M, Raffeld M, Mateo C, Sakamoto A, Moody TW, Ito T, Venzon DJ, Serrano J, Jensen RT 2005 Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases. Clin Cancer Res 11:3233-3242
20. Ho PK, Fong RS, Kai HS, Lau EH, Ngan ES, Cotton CU, Chow BK 1999 The human secretin receptor gene: genomic organization and promoter characterization. FEBS Lett 455:209-214
21. Jensen RT 1999 Natural history of digestive endocrine tumors. In: Mignon M, Colombel JF, eds. Recent advances in pathophysiology and management of inflammatory bowel diseases and digestive endocrine tumors. Paris: John Libbey Eurotext Publishing Co.; 192-219
22. Coussens CM, Williams JM, Ireland DR, Abraham WC 2000 Tyrosine phosphorylation-dependent inhibition of hippocampal synaptic plasticity. Neuropharmacology 39:2267-2277
23. Ding WQ, Cheng ZJ, McElhiney J, Kuntz SM, Miller LJ 2002 Silencing of secretin receptor function by dimerization with a misspliced variant secretin receptor in ductal pancreatic adenocarcinoma. Cancer Res 62:5223-5229
24. Korner M, Hayes GM, Rehmann R, Zimmermann A, Friess H, Miller LJ, Reubi JC 2005 Secretin receptors in normal and diseased human pancreas: marked reduction of receptor binding in ductal neoplasia. Am J Pathol 167:959-968
25. Isenberg JI, Walsh JH, Passaro Jr E, Moore EW, Grossman ME 1972 Unusual effect of secretin on serum gastrin, serum calcium and gastric acid secretion in a patient with suspected Zollinger- Ellison syndrome. Gastroenterology 62:626-631
26. Brady CE, Utts SJ, Dev J 1987 Secretin provocation in normal and duodenal ulcer subjects. Is the gastrin rise in Zollinger-Ellison syndrome paradoxic or exaggeration? Dig Dis Sci 32:232-238
27. Elouaer-Blanc L, Sobhani I, Ruszniewski P, Duet M, Lehy T, Mignon M, Bonfils S, Lewin MJ 1988 Gastrin secretion by gastrinoma cells in long-term culture. Am J Physiol 255(5 Pt 1):G596-G602
28. Gower Jr WR, Ellison EC, Knierim TH, Elkhammas EA, O'Dorisio TM, Fabri PJ 1990 Gastrinoma in vitro: morphological and physiological studies of primary cell cultures. Gastroenterology 98:936-954
29. Imamura M, Adachi H, Takahashi K, Noguchi M, Mizutani N, Nakagawa M, Tobe T 1982 Gastrin release from gastrinoma cells stimulated with secretin. Dig Dis Sci 27:1130-1136
30. Raggi CC, Maggi M, Renzi D, Calabro A, Bagnoni ML, Scaruffi P, Tonini GP, Pazzagli M, De Bernardi B., Bernini G, Serio M, Orlando C 2000 Quantitative determination of sst2 gene expression in neuroblastoma tumor predicts patient outcome. J Clin Endocrinol Metab 85:3866-3873
31. Papotti M, Croce S, Macri L, Funaro A, Pecchioni C, Schindler M, Bussolati G 2000 Correlative immunohistochemical and reverse transcriptase polymerase chain reaction analysis of somatostatin receptor type 2 in neuroendocrine tumors of the lung. Diagn Mol Pathol 9:47-57
32. Passaro Jr E, Howard TJ, Sawicki MP, Watt PC, Stabile BE 1998 The origin of sporadic gastrinomas within the gastrinoma triangle: a theory. Arch Surg 133:13-16
33. Bold RJ, Lowry PS, Ishizuka J, Battey JF, Townsend Jr CM, Thompson JC 1994 Bombesin stimulates the in vitro growth of a human gastric cancer cell line. J Cell Physiol 161:519-525
34. Ahlman H, Ahlund L, Dahlstrom A, Theodorsson E 1989 Expression of gastrointestinal endocrine tumours in culture systems. Arch Histol Cytol 52(Suppl):233-240
35. Woltering EA, Ellison EC, O'Dorisio TM, Hitchcock C, Roberts K, Stephens R, Sparks J, Carey LC 1985 Gastrin release from dispersed gastrinoma cells: effects of calcium and calcium ionophore (A23187). J Surg Res 39:331-337
36. Edwards BF, Redding TW, Schally AV 1989 The effect of gastrointestinal hormones on the incorporation of tritiated thymidine in the pancreatic adenocarcinoma cell line (WD PaCa). Int J Pancreatol 5:191-201
37. Ohyama K 1985 [Effects of anti-tumor drugs and gastrointestinal hormones on the growth of pancreatic duct cell adenocarcinoma in homologous transplanted animal models]. Hokkaido Igaku Zasshi 60:206-216 (Japanese)
38. Tanaka J, Yamaguchi T, Takahashi T, Ogata N, Bando K, Koyama K 1986 Regulatory effects of gastrin and secretin on carcinomas of the stomach and colon. Tohoku J Exp Med 148:459-460
39. Kilpatrick GJ, Dautzenberg FM, Martin GR, Eglen RM 1999 7TM receptors: the splicing on the cake. Trends Pharmacol Sci 20:294-301
40. Ando S, Sarlis NJ, Krishnan J, Feng X, Refetoff S, Zhang MQ, Oldfield EH, Yen PM 2001 Aberrant alternative splicing of thyroid hormone receptor in a TSH-secreting pituitary tumor is a mechanism for hormone resistance. Mol Endocrinol 15:1529-1538
41. Sarmiento JM, Anazco CC, Campos DM, Prado GN, Navarro J, Gonzalez CB 2004 Novel down-regulatory mechanism of the surface expression of the vasopressin V2 receptor by an alternative splice receptor variant. J Biol Chem 279:47017-47023
42. Edwards SW, Tan CM, Limbird LE 2000 Localization of G-protein-coupled receptors in health and disease. Trends Pharmacol Sci 21:304-308
43. Kim HJ, Woo IS, Kang ES, Eun SY, Kim HJ, Lee JH, Chang KC, Kim JH, Seo HG 2006 Identification of a truncated alternative splicing variant of human PPAR-gamma1 that exhibits dominant negative activity. Biochem Biophys Res Commun 347:698-706
44. Chen S, Lin F, Xu M, Hwa J, Graham RM 2000 Dominant-negative activity of an alpha(1B)-adrenergic receptor signal-inactivating point mutation. EMBO J 19:4265-4271
45. Grosse R, Schoneberg T, Schultz G, Gudermann T 1997 Inhibition of gonadotropin-releasing hormone receptor signaling by expression of a splice variant of the human receptor. Mol Endocrinol 11:1305-1318
46. Seck T, Pellegrini M, Florea AM, Grignoux V, Baron R, Mierke DF, Horne WC 2005 The δ e13 isoform of the calcitonin receptor forms a six-transmembrane domain receptor with dominant-negative effects on receptor surface expression and signaling. Mol Endocrinol 19:2132-2144
47. Norton JA, Alexander HA, Fraker DL, Venzon DJ, Gibril F, Jensen RT 2003 Possible primary lymph node gastrinomas: occurrence, natural history and predictive factors: a prospective study. Ann Surg 237:650-659